Chemotherapy-induced Secondary Malignancies

Journal of Infusion Nursing

Volumn 26, Issue 6, 2003, Pages 353-361

  Vega Stromberg, Teri ^a  

^a Wheaton Franciscan Healthcare St Joseph's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; CHLORMETHINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; PROCARBAZINE; TENIPOSIDE;

BONE MARROW CELL; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DNA REPLICATION; DRUG MEGADOSE; EPITHELIUM CELL; GASTROINTESTINAL TRACT; HAIR FOLLICLE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MONOCYTE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; TESTIS CARCINOMA;

AFTERCARE; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; COCARCINOGENESIS; DNA TOPOISOMERASES, TYPE II; FAMILY; HUMANS; INFORMATION SERVICES; NEOPLASMS, SECOND PRIMARY; NURSE'S ROLE; ONCOLOGIC NURSING; PATIENT EDUCATION; RISK FACTORS; SURVIVORS;

EID: 0345714991     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200311000-00004     Document Type: Review

References (40)

1. Koopmeiners L, Post-White J, Gutknecht S, et al. How healthcare professionals contribute to hope in patients with cancer. Oncol Nurs Forum. 1997;24(9):1507-1513.
2. American Cancer Society. Cancer Facts and Figures 2002. Atlanta: American Cancer Society; 2002.
3. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2001;51:15-36.
4. Ries LG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute; 2000. NIH publication number 00-2789.
5. Schusterman S, Meadows AT. Long-term survivors of childhood leukemia. Curr Opin Hematol. 2000;7:217-220.
6. Rowland J, Aziz N, Tesauro G, Feuer E. The changing face of cancer survivorship. Semin Oncol Nurs. 2001;17(4):236-240.
7. Fraser MC, Tucker MA. Late effects of cancer therapy: chemotherapy related malignancies. Oncol Nurs Forum. 1988;15:67-77.
8. Ganz P. Late effects of cancer and its treatment. Semin Oncol Nurs. 2001;17(4):241-248.
9. Rodriguez C, Ash CR. Programmed instruction: cancer therapy: associated late effects. Cancer Nurs. 1996;19(6):455-464.
10. Rosenthal PE. Complications of cancer and cancer treatment. In: Lenhard RE, Osteen RT, Gansler T, eds. Clinical Oncology. Atlanta: American Cancer Society; 2001:232-248.
11. Van Leeuwen F, Travis L. Adverse effects of treatment, second cancers. In: Devita VT, Hillman S, Rosenberg SA, eds. Cancer Principles & Practice Of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:2939-2965.
12. Armitage JO. Myelodysplasia and acute leukemia after autologous bone marrow transplantation. J Clin Oncol. 2000;18(5):945-946.
13. Henry-Amar M, Dietrick PY. Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am. 1993;7:369-387.
14. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(suppl):115-118.
15. Meadows AT, Obringer AC, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and spleenectomy as risk factors. Medical and Pediatric Oncology. 1989;17:477-484.
16. Sitzia J, North C, Stanley J, et al. Side effects of CHOP in the treatment of non-Hodgkin's lymphoma. Cancer Nurs. 1997;20:430-439.
17. Fernsler J, Fanuele J. Lymphomas: long-term sequelae and survivorship issues. Sem Oncol Nurs. 1998;14(4):321-328.
18. Travis LB, Curtis RE, Glimeluis B, et al. Second cancers among long-term survivors of non-Hodgkin's disease. J Natl Cancer Inst. 1993;85:1932-1937.
19. Micallef I, Lillington D, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18(5):947-955.
20. Friedberg J, Neuberg D, Stone R, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(10):3128-3135.
21. Krishman A, Bhatia S, Slovak ML, et al. Predictors of therapy related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95(5):1588-1593.
22. Bokemeyer C, Berger CC, Kurczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996;14:2923-2932.
23. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89:1429-1439.
24. Boshoff C, Bergen RH, Oliver RT, et al. Secondary tumors following etoposide containing therapy for germ cell cancer. Ann Oncol. 1995;6:35.
25. Travis LB, Holoway EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340-351.
26. Travis LB, Curtis RE, Boice JD, et al. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res. 1996;56:1564.
27. Ganz PA, Rowland JH, Meyerowitz BE, et al. Impact of different adjuvant strategies on quality of life in breast cancer survivors. Recent Results & Cancer Review. 1998;152:396-411.
28. Rubino C, de Vathaire F, Diallo I, et al. Increased risk of second cancer following breast cancer: role of the initial treatment. Breast Cancer Res Treat. 2000;61(3);183-195.
29. Chaplain G, Milan C, Sgro C, et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol. 2000;18(15):2836-2842.
30. Berstein L, Deapen D, Certhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91:1654.
31. Bhatia S, Robinson LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Eng J Med. 1996;334:745.
32. Wolden SL, Lamborn KR, Cleary DF, Tate DJ, Donaldson SS. Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998;16(2):536-544.
33. Green D, Hyland A, Barcos M, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol. 2000;18(7):1492-1499.
34. Breslow NE, Takashima JR, Whitton JA, Moksness J, D'Anglo GJ, Green DM. Second malignant neoplasms following treatment for Wilm's tumor. A report from the national Wilm's tumor study group. J Clin Oncol. 1995;13(8):1851-1859.
35. Scaradavou A. Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma. Cancer. 1995;76(10):1860-1867.
36. Curtis RE, Rowlings PA, Deey HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897-904.
37. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasm after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325(19):1330-1336.
38. Richardson RC, Nelson MB, Meeske K. Young adult survivors of childhood cancer: attending to medical and psychosocial needs. J Pediatr Oncol. 1999;16(3):136-144.
39. Ward JD. Pediatric cancer survivors: assessment of late effects. Nurse Pract. 2000;25(12):21-2,24-28.
40. Roberts CS, Severinsen C, Carraway C, et al. Life changes and problems experienced by young adults with cancer. J Psychosoc Oncol. 1997;15:15-25.